Gene therapy
Executive Summary
FDA Biological Response Modifiers Advisory Committee will discuss agency's proposed rule on public disclosure of gene therapy trials at April 5-6 meeting (1"The Pink Sheet" Jan. 22, p. 23). The committee will review results from gene therapy clinical site inspections and long-term follow-up of gene therapy patients. The meeting will take place at the Holiday Inn in Bethesda, Md., beginning at 9 a.m. on April 5 and 8:30 a.m. on April 6